What is RayzeBio?
RayzeBio is a clinical-stage radiopharmaceutical company focused on improving outcomes for patients with cancer. The company leverages the power of targeted radioisotopes, specifically alpha-emitters like Actinium-225, to deliver potent therapeutic payloads directly to cancer cells. By concentrating on clinically validated solid tumor targets, RayzeBio aims to offer a more precise and effective treatment modality compared to traditional therapies. The company's approach involves developing novel drug conjugates designed to selectively bind to cancer cells, thereby minimizing damage to healthy tissues and enhancing therapeutic efficacy. This innovative strategy positions RayzeBio at the forefront of a rapidly evolving field within oncology, seeking to address significant unmet medical needs.
How much funding has RayzeBio raised?
RayzeBio has raised a total of $418M across 4 funding rounds:
Series A
$45M
Series B
$105M
Series C
$108M
Series D
$160M
Series A (2020): $45M with participation from Samsara Bio-Pharma, Versant Ventures GmbH, and venBio Partners LLC
Series B (2020): $105M led by OrbiMed, Logos Capital, Viking Global Investors, Alexandria Venture Investments, Cormorant Asset Management, LifeSci Venture Partners, Redmile Group, and Venrock Healthcare Capital Partners
Series C (2021): $108M supported by Alexandria Venture Investments, Logos Capital, Vivo Capital, Perceptive Advisors, Samsara BioCapital, TCG X, LifeSci Venture Partners, Versant Ventures, venBio Partners, Cormorant Asset Management, HealthQuest Capital, OrbiMed, Redmile Group, Viking Global Investors, and Deerfield
Series D (2022): $160M featuring Ally Bridge Group, Viking Global Investors, Wellington Management, and Sands Capital
Key Investors in RayzeBio
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various stages of development with deep expertise in life sciences and healthcare business development.
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis across industries and geographies. They select public and private equity interests.
Alexandria Venture Investments
Alexandria Venture Investments, part of Alexandria Real Estate Equities, Inc., is a real estate investment trust focused on the life sciences industry, providing properties for lease to pharmaceutical, biotechnology, and research entities.
What's next for RayzeBio?
With the recent influx of major strategic investment, RayzeBio is poised to accelerate its development pipeline and expand its operational capabilities. The substantial capital infusion, part of its overall $418M in financing, will likely be directed towards advancing its lead drug candidates through clinical trials, further validating the efficacy and safety of its targeted radioisotope therapies. This strategic backing also enables RayzeBio to scale its manufacturing processes, enhance its research and development efforts, and potentially explore new therapeutic targets. The company's trajectory suggests a strong focus on achieving key clinical milestones and solidifying its position as a leader in the radiopharmaceutical space, with potential for future partnerships or market expansion.
See full RayzeBio company page
